Enjoy complimentary customisation on priority with our Enterprise License!
The bile duct cancer market share is expected to increase by USD 105.55 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 7.79%.
This bile duct cancer market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers bile duct cancer market segmentation by type (extrahepatic bile duct cancer and intrahepatic bile duct cancer) and geography (North America, Europe, Asia, and ROW). The bile duct cancer market report also offers information on several market vendors, including AstraZeneca Plc, BridgeBio Pharma Inc., Bristol-Myers Squibb Co., Hutchison China Meditech Ltd., Incyte Corp., J-Pharma Co. Ltd., Merck KGaA, RemeGen Co. Ltd, Servier, and Sino Biopharmaceutical Ltd. among others.
Download the Free Report Sample to Unlock the Bile Duct Cancer Market Size for the Forecast Period and Other Important Statistics
The growing preference for chemotherapy drugs in developing countries is notably driving the bile duct cancer market growth, although factors such as lack of adequate healthcare infrastructure in developing nations may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the bile duct cancer industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Bile Duct Cancer Market Driver
Although the preference for chemotherapy drugs in developed countries has been on a decline, the use of chemotherapy drugs in combination with other therapies remains strong. For instance, researchers have evaluated the use of combination drugs that include chemotherapy drugs as well as targeted therapies. This should offset the impact of the reduced demand for chemotherapy drugs in developed countries. For instance, 5 fluorouracil (5-FU) is a cytotoxic chemotherapy medication used to treat bile duct cancer. The adoption of this medication has led to a significant rate of improvement in the overall survival rate and an almost equal rate of increase in the disease-free survival rate. On the other hand, in developing countries, there is an increased preference for chemotherapy, which is still considered as a gold standard for cancer treatment in those countries. In developing regions such as China and India, the demand for targeted therapies is still in the nascent phase. Therefore, physicians still prefer chemotherapy for the treatment of cancer.
Key Bile Duct Cancer Market Challenge
Radiotherapy and chemotherapy devices require ample installation space due to their large size. In underdeveloped and emerging economies such as India, Argentina, African countries, there is a lack of adequate healthcare infrastructure due to limited healthcare expenditure. This is one of the major factors restraining the adoption of cancer treatment in countries such as India, Brazil, and South Africa. Only a limited number of healthcare institutions in underdeveloped and developing countries can use advanced radiotherapy systems for cancer treatment. This, in turn, limits the number of radiotherapy and chemotherapy procedures despite their high demand.
This bile duct cancer market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the bile duct cancer market encompasses successful business strategies deployed by the key vendors. The bile duct cancer market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The bile duct cancer market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
For more insights on the market share of various regions Request for a FREE sample now!
41% of the market's growth will originate from North America during the forecast period. The US is a key market for bile duct cancer in North America. However, the market growth rate in this region will be slower than the growth of the market in Asia.
Considerable investments in the pharmaceutical industry, specifically the oncology sector, and the presence of pharmaceutical giants will facilitate the bile duct cancer market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
To gain further insights on the market contribution of various segments Request for a FREE sample
The bile duct cancer market share growth by the extrahepatic bile duct cancer segment will be significant during the forecast period. Extrahepatic bile duct cancer is rare cancer that forms in the bile duct outside the liver. There are several types of extrahepatic bile duct cancer according to the point of origin, such as perihilar (or hilar) bile duct cancer at the point where the bile duct leaves the liver and comes outside, and distal bile duct cancer a pipeline located further away from the liver and closer to the small intestine and the pancreas.
This report provides an accurate prediction of the contribution of all the segments to the growth of the bile duct cancer market size and actionable market insights on post COVID-19 impact on each segment.
Bile Duct Cancer Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 7.79% |
Market growth 2022-2026 |
$ 105.55 million |
Market structure |
Fragmented |
YoY growth (%) |
7.10 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 41% |
Key consumer countries |
US, Germany, UK, China, and Japan |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
AstraZeneca Plc, BridgeBio Pharma Inc., Bristol-Myers Squibb Co., Hutchison China Meditech Ltd., Incyte Corp., J-Pharma Co. Ltd., Merck KGaA, RemeGen Co. Ltd, Servier, and Sino Biopharmaceutical Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Type
Customer landscape
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.